<DOC>
	<DOCNO>NCT02349867</DOCNO>
	<brief_summary>This phase 1 study concurrent chemoradiation use regimen sorafenib vorinostat gemcitabine radiation follow chemotherapy patient pancreatic cancer find RP2D concurrent chemoradiation combination . A traditional 3+3 dose-escalation design conduct sorafenib vorinostat dose escalation . Adenocarcinoma pancreas without distant metastasis treat ≥ 1 prior therapy ( include radiation ) encompass least 2 month . Adequate hematologic , hepatic , renal function . Ability take oral medication . To determine dos schedule appropriate phase 2 study sorafenib vorinostat concurrent gemcitabine radiation therapy ( RT ) neoadjuvant treatment pancreatic cancer follow chemotherapy .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Followed Concurrent Chemoradiation With Gemcitabine , Sorafenib Vorinostat Resectable , Borderline Resectable Unresectable Non-metastatic Pancreas Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine dos schedule appropriate phase 2 study sorafenib vorinostat concurrent gemcitabine radiation therapy ( RT ) neoadjuvant treatment pancreatic cancer follow chemotherapy . SECONDARY OBJECTIVES : I . To evaluate safety toxicity concurrent chemoradiation use regimen sorafenib , vorinostat , gemcitabine , RT follow chemotherapy . II . To observe antitumor effect regimen . III . To evaluate percentage patient able undergo resection neoadjuvant therapy ( chemotherapy follow concurrent chemoradiation ) . IV . To calculate R0 ( complete removal tumor ) resection rate follow chemoradiation . V. To evaluate progression-free survival ( PFS ) . VI . To evaluate overall survival ( OS ) . TERTIARY OBJECTIVES : I . To assess feasibility analyze pancreatic patient circulate tumor cell ( CTCs ) enumeration caspase 3 cleavage concurrent chemoradiation . II . To characterize pancreatic tumor ( sufficient tissue sample available ) expression cluster differentiation ( CD ) 95 , myeloid cell leukemia ( MCL ) 1 , platelet-derived growth factor receptor ( PDGFR ) evaluate archive tumor tissue diagnostic biopsy compare tissue obtain time resection chemoradiation . OUTLINE : This dose-escalation trial employ standard `` 3+3 '' schema sorafenib vorinostat . After completion study treatment , patient follow 30 day every 2-3 month 2 year death .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Adenocarcinoma pancreas Prior therapy ≥ 1 prior systemic therapy period least 2 month ( eg , least two 4week cycle regimen gemcitabine nabpaclitaxel ; least four 2week cycle regimen FOLFOX , FOLFIRINOX , FOLFIRI ) Candidate additional therapy consist radiation gemcitabine radiosensitization . Able initiate study treatment later 6 week last dose antineoplastic component prior therapy regimen . Recovery ≥ grade 2 toxicity prior therapy regimen grade 1 baseline , exception anemia lymphopenia . Patients ≤ grade 2 peripheral sensory motor neuropathy eligible . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 3 x upper limit normal ( ULN ) laboratory Total bilirubin = &lt; 1.5 x ULN laboratory time enrollment , form biliary stent allow Creatinine clearance &gt; = 45 mL/min calculate standard CockcroftGault equation use age , actual weight , creatinine gender International normalize ratio ( INR ) = &lt; 1.5 Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelets &gt; = 100,000/mm^3 ( may transfuse meet level enrollment ) Measurable evaluable disease Response Evaluation Criteria Solid Tumors ( RECIST ) ( version [ v ] 1.1 Ability understand willingness sign write informed consent document Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential men must agree use medically accept form birth control treatment 2 month follow completion study treatment Prior radiotherapy pancreatic cancer Prior surgical resection pancreatic cancer Evidence metastatic disease Any investigational agent within 4 week study treatment initiation Diagnosis treatment another malignancy within 3 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Intolerance protocol agent follow : Known presumed intolerance gemcitabine , vorinostat sorafenib Experienced follow toxicity prior gemcitabine adminstration ( give ) : capillary leak syndrome , posterior reversible encephalopathy , hemolytic uremic syndrome , thrombotic thrombocytopenic purpura , unexplained dyspnea evidence severe pulmonary toxicity , severe hepatic toxicity Unable swallow medication Suspected malabsorption obstruction ; note : use pancreatic enzyme supplement allow control malabsorption Contraindication antiangiogenic agent , include : Bronchopulmonary hemorrhage/bleeding event &gt; = grade 2 ( Common Terminology Criteria Adverse Events [ CTCAE ] v4.0 ) within 12 week prior treatment Any hemorrhage/bleeding event &gt; = grade 3 ( CTCAE v4.0 ) within 12 week prior initiation treatment Serious nonhealing wound , ulcer , bone fracture Arterial thrombotic embolic event myocardial infarction cerebrovascular accident ( include transient ischemic attack ) within 6 month prior initiation treatment . Incidental clinically insignificant embolic phenomenon require anticoagulant exclude . Also , tumorassociated thrombus locallyinvolved vessel count exclusion criterion . Clinically significant cardiac disease , include major cardiac dysfunction , uncontrolled angina , clinical congestive heart failure New York Heart Association ( NYHA ) class III IV , ventricular arrhythmia require antiarrhythmic therapy , recent ( within 6 month ) myocardial infarction unstable coronary artery disease Concomitant use histone deacetylase ( HDAC ) inhibitor Planned ongoing administration STRONG cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inducer Persistent heart rate ( HR ) &lt; 50 &gt; 120 beat per minute ( bpm ) . Corrected QT ( c ) ≥ 481 m ( &gt; = grade 2 ) electrocardiogram ( ECG ) prior initiation treatment If baseline QTc screen ECG meet exclusion criterion : Check potassium magnesium serum level Correct identify hypokalemia and/or hypomagnesemia repeat ECG confirm exclusion patient due QTc For patient HR 60100 beat per minute ( bpm ) , manual read QTc require For patient baseline HR &lt; 60 &gt; 100 bpm , manual read QT cardiologist require , Fridericia correction apply determine QTc Planned ongoing treatment drug think potentially adversely interact study drug ; medication use , patient must agent &gt; = 2 week prior initiation treatment : Anticoagulants therapeutic dos Immunosuppressants tacrolimus , leflunomide tofacitinib , roflumilast , pimecrolimus Serious uncontrolled infection &gt; grade 2 ( CTCAE v4.0 ) Medical , psychological , social condition , opinion investigator , may increase patient 's risk interfere patient 's participation study hinder evaluation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>